Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4154336

COC[C@@H](N)c1nc2cc(Cl)ccc2[nH]1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
S1PR4 O95977 7/20 0.47
S1PR1 P21453 7/20 0.47
S1PR5 Q9H228 6/20 0.47
SCN10A Q9Y5Y9 2/20 0.39
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38
CTDSP1 Q9GZU7 1/20 0.38
ROCK2 O75116 2/20 0.37
PYGL P06737 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PRCP P42785 1/20 0.36
DPP4 P27487 1/20 0.36
DPP7 Q9UHL4 1/20 0.36
AAK1 Q2M2I8 1/20 0.35
TAAR1 Q96RJ0 1/20 0.35
SIRT1 Q96EB6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4164102 1.00 S1PR4 (0.47) S1PR4S1PR1S1PR5SCN10AOPRM1
Trifluoroacetic Acid SCHEMBL4166142 0.93 S1PR4 (0.45) S1PR4S1PR1S1PR5SCN10AOPRM1
SCHEMBL1479674 0.89 TAAR1 (0.43) SCN10AROCK2PYGLAAK1TAAR1
SCHEMBL4162306 0.89 TAAR1 (0.43) SCN10AROCK2PYGLAAK1TAAR1
SCHEMBL583539 0.89 TAAR1 (0.43) SCN10AROCK2PYGLAAK1TAAR1
Trifluoroacetic Acid SCHEMBL4157721 0.86 S1PR4 (0.46) S1PR4S1PR1S1PR5SCN10AOPRM1
Trifluoroacetic Acid SCHEMBL4156410 0.86 S1PR4 (0.51) S1PR4S1PR1S1PR5SCN10AOPRM1
Trifluoroacetic Acid SCHEMBL4144867 0.84 S1PR4 (0.44) S1PR4S1PR1S1PR5SCN10AOPRM1
Trifluoroacetic Acid SCHEMBL4146413 0.83 S1PR4 (0.44) S1PR4S1PR1S1PR5SCN10ASMN1; SMN2
Trifluoroacetic Acid SCHEMBL4153478 0.83 S1PR4 (0.43) S1PR4S1PR1S1PR5SCN10AOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181958-A1 SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-07-16 US disclosed
US-7429597-B2 Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) 2008-09-30 US disclosed
EP-1583757-A1 NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2005-10-12 EP disclosed
US-20040176603-A1 Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-09-09 US disclosed
WO-2004058743-A1 NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176603-A1 Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions F11, F12, F2 S1PR4 4711/4885S1PR1 3898/4885S1PR5 4042/4885
US-20090181958-A1 SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS F12, F11, F2 S1PR4 4618/4885S1PR1 4147/4885S1PR5 4160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.